# Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function

> **NCT01569828** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Pharmacokinetics
- Renal Impaired
- Healthy Volunteer

## Interventions

- **DRUG:** LCZ696A
- **DRUG:** LCZ696A

## Key facts

- **NCT ID:** NCT01569828
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569828, "Multiple Dose Pharmacokinetics of LCZ696 and Its Metabolites in Subjects With Severe Renal Impairment vs. Matched Healthy Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01569828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*